AgomAb (NASDAQ: AGMB) director Epstein lifts holding 60% in a share purchase

What happened

Director David R. Epstein bought 15,000 shares of AgomAb Therapeutics NV (NASDAQ: AGMB) on Nov. 5, taking the director's holding to 40,000 shares. By OptimistFi's calculation, the purchase equals 60.0% of the 25,000 shares Epstein held beforehand.

Epstein bought three blocks of 5,000 shares each. The prices were $6.81, $6.91 and $6.98 per share, each block priced above the one before it, for a total of about $103,500. The filing lists the shares as directly owned.

The filing says the common shares may be represented by American Depositary Shares, each of which currently represents one common share. Ellen Lefever signed the Form 4 as attorney-in-fact on Nov. 6.

Key numbers

Metric	Latest	Change	Source
Shares bought by Epstein	15,000 shares		SEC Form 4
Price range per share	$6.81 to $6.98		SEC Form 4
Total purchase amount	about $103,500		SEC Form 4
Shares held after the purchase	40,000 shares	+60.0%	Calculated from SEC Form 4

Read more: AgomAb Therapeutics (AGMB) company research

Why it matters

This is a purchase, not a sale, and it enlarged an existing position rather than opening a new one. For a holder, that makes it a directional data point from someone on the board. Reading it well means weighing size and direction, not guessing at motive.

The buying came in three blocks at rising prices, and the filing reports the shares as directly owned, so the stake is held in Epstein's own name. Because each American Depositary Share currently represents one common share, the holding reads the same whether counted in common shares or in depositary shares.

OptimistFi has no investment case on file for AgomAb, so the filing sets a baseline rather than confirming or challenging a thesis. It records where one director stood after Nov. 5 and gives a reference point for judging later insider activity.

The purchase is one director's trade. It does not establish operating performance or business momentum, and it does not show that the buying will continue.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

AgomAb's next quarterly report is the next scheduled test of the stock. Stronger operating results there would line up with the purchase. Weaker ones would leave it standing alone as a single insider trade.

More from OptimistFi

• AGMB stock: research and coverage of AgomAb Therapeutics
• Stock research on every company OptimistFi covers

From OptimistFi Perps